| Enrolling By Invitation | Intra Ovarian Muse Cell Injection for Perimenopause Symptom Relief and Ovarian Function Restoration (MUSE-OVAR NCT07511660 | Healing Hope International | — |
| Recruiting | Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Me NCT06957691 | Shehzad Basaria, M.D. | Phase 2 |
| Recruiting | Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture NCT07335224 | Inova Health Care Services | N/A |
| Recruiting | Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause NCT07112651 | ApexCPG LLC | N/A |
| Completed | A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elin NCT07229404 | Bayer | Phase 1 |
| Recruiting | Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). NCT07042516 | Tioga Pharmaceuticals | Phase 2 |
| Enrolling By Invitation | Vasomotor Symptoms in Post-Hysterectomy Women With Ovarian Conservation NCT07064850 | Northwestern University | — |
| Recruiting | JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women NCT07238478 | Bonafide Health | N/A |
| Recruiting | Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong NCT06628388 | The University of Hong Kong | N/A |
| Not Yet Recruiting | A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women NCT06393673 | Hansoh BioMedical R&D Company | Phase 2 |
| Completed | Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women NCT07408115 | Bonafide Health | N/A |
| Completed | A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers NCT06204250 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Study of HS-10384 in Participants of Chinese Postmenopausal Women NCT06122181 | Hansoh BioMedical R&D Company | Phase 1 |
| Completed | Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women NCT05813067 | Bonafide Health | N/A |
| Completed | Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women NCT05367973 | Daré Bioscience, Inc. | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms NCT05637671 | Cairo University | Phase 3 |
| Completed | A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause NCT05033886 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Completed | A Survey About Hot Flashes in Women Going Through the Menopause NCT05083884 | Astellas Pharma Europe Ltd. | — |
| Completed | FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms NCT05312567 | Fervent Pharmaceuticals | Phase 2 |
| Completed | A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Health NCT05418426 | Daré Bioscience, Inc. | Phase 1 |
| Completed | Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I NCT04209543 | Estetra | Phase 3 |
| Completed | Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II) NCT04090957 | Estetra | Phase 3 |
| Completed | The Effect of Health Education and Progressive Muscle Relaxation Exercise on Vasomotor Symptoms and Sleep Prob NCT04808232 | Sidika Pelit Aksu | N/A |
| Withdrawn | Stellate Ganglion Blockade in Post-Menopausal Women NCT02907983 | Northwestern University | Phase 2 |
| Completed | Determination of the Effects of Autogenic Relaxation Exercise and Cold Pillow Application on Vasomotor Symptom NCT05850338 | Aylin Güneş | N/A |
| Completed | HIRREM Hot Flashes Study NCT03512002 | Wake Forest University Health Sciences | N/A |
| Terminated | Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer NCT03122301 | Northwestern University | Phase 2 |
| Completed | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Su NCT02803268 | Tanabe Pharma Corporation | Phase 1 |
| Terminated | Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor NCT02653417 | Radius Pharmaceuticals, Inc. | Phase 2 |
| Withdrawn | Vasomotor Symptoms and Cardiovascular Control NCT02202707 | Beth Israel Deaconess Medical Center | N/A |
| Terminated | Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients NCT01353963 | Pfizer | — |
| Unknown | A Study of MF101 in Postmenopausal Women NCT00906308 | Bionovo | Phase 3 |
| Completed | Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women NCT01452373 | EndoCeutics Inc. | Phase 3 |
| Completed | Acupuncture in Menopause NCT01276028 | Wake Forest University Health Sciences | N/A |
| Completed | MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercis NCT01178892 | Fred Hutchinson Cancer Center | N/A |
| Completed | Effect of Yoga on Objective and Subjective Menopausal Hot Flashes NCT01073397 | Wake Forest University | N/A |
| Completed | Duloxetine for Menopausal Depression NCT01117857 | Massachusetts General Hospital | Phase 4 |
| Completed | MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women NCT00894543 | Fred Hutchinson Cancer Center | N/A |
| Completed | Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Wome NCT00683800 | Pfizer | Phase 3 |
| Completed | Low-dose Hormone Therapy for Relief of Vasomotor Symptoms NCT00446199 | Bayer | Phase 3 |
| Completed | Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway NCT00456898 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms NCT00401245 | Pfizer | Phase 3 |
| Completed | Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women NCT00397176 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. NCT00356447 | Bayer | Phase 3 |
| Completed | Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal Women NCT00472004 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | Mindfulness-Based Stress Reduction for Hot Flashes NCT01052454 | University of Massachusetts, Worcester | EARLY_Phase 1 |
| Completed | Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (461 NCT00560833 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (17 NCT00535288 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Treatment of Vasomotor Symptoms in Korean Post Menopausal Women NCT00651599 | Bayer | Phase 3 |
| Completed | Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopaus NCT00421031 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrog NCT00332553 | Eli Lilly and Company | Phase 2 |